Clinical Trial Update: Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a trimodality approach using low-dose ionizing radiation with or without neoadjuvant pembrolizumab followed by prostatectomy for inte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Duke University | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN